Hepatic fibrosis: Concept to treatment

Area of Science:

• * Molecular mechanisms of liver fibrogenesis and fibrosis regression.
• * Translational research in antifibrotic drug development.

Background:

• * Antiviral treatments offer insights into fibrosis regression and identify therapeutic targets.
• * Numerous compounds demonstrate antifibrotic potential in vitro and in animal models, but lack clinical validation.
• * Current therapeutic strategies for liver fibrosis are limited, necessitating novel approaches.

Purpose of the Study:

• * To highlight the need for etiological-independent treatments for liver fibrogenesis.
• * To emphasize the importance of validating antifibrotic drug targets and combination therapies.
• * To underscore the necessity of improved noninvasive tools for fibrosis assessment in clinical trials.

Main Methods:

• * Review of current understanding of liver fibrogenesis and fibrosis regression.
• * Analysis of preclinical and clinical data for antifibrotic compounds.
• * Discussion of challenges and future directions in antifibrotic drug development and clinical trial design.

Main Results:

• * Antiviral therapies provide valuable information on fibrosis regression.
• * No antifibrotic drug has been clinically validated or commercialized.
• * Combination therapies targeting multiple pathways are likely necessary for effective treatment.

Conclusions:

• * Further research into molecular mechanisms of liver fibrogenesis is essential.
• * Preclinical development requires reliable single target validation and systematic testing of combination therapies.
• * Standardized clinical trial designs and noninvasive assessment tools are critical for advancing antifibrotic drug development.